Updated 15 September 2023
Introduction
Here you can find an overview of clinical trials that are ongoing in hospitals that are part of the ECFS Clinical Trials Network (CTN). For studies that are finished, the study results are posted as soon as they are available.
Here you find the full list of European CF centers making out the network.
Studies only run in CTN sites after a formal review of the study protocol and approval by a committee of experts. This does not mean that all CTN centers will participate in a specific study. Each study overview sheet will list the participating CTN sites. Some CTN approved studies also run in additional centers that are not part of the CTN network. A complete list of participating sites can be found on the specific www.clinicaltrials.gov (link is external) that is mentioned on each study overview sheet.
In case you want to participate in some of the trials listed here, please consult your treating physician/doctor. The overview lists the studies under: "recruitment started" or under "recruitment finished". In addition, the studies are categorized according to the drug's mechanism of action:
- Genetic Therapy
- Restore CFTR Protein
- Mucus Alteration
- Mucociliary Clearance
- Anti-Inflammatory
- Anti-Infective
- Restore Airway Surface Liquid
- Mucus Alteration
- Bronchodilatators
- Nutritional-GI
- Other
The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up to date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information:
ECFS-CTN@uzleuven.be (link sends e-mail)
Overview of Studies
Recruitment Started in CTN sites:
Genetic Therapy
Restore CFTR Protein
Anti-Infective
Other
Recruitment Completed in CTN sites:
Restore CFTR function
- PTC 124 - Includes Study Results (in PDF)
- PTC 124 extension + study results
- Vertex VX12-770-111+ study results
- Vertex VX11-770-110 + study results
- Vertex VX12-809-103 + study results
- Vertex VX12-809-104 + study results
- Vertex VX11-770-108 + study results
- Vertex VX-809 alone and combined with VX-770 + study results
- Vertex VX11-661-101 + study results
- Vertex VX12-770-112 (extension) + study results
- Vertex VX12-809-105 (extension) + study results
- Vertex VX11-770-109 (extension) + study results
- PTC124-GD-021-CF (ACT CF)
- Novartis CQBW25X2101 + study results
- Vertex VX14-661-106 + study results
- Vertex VX14-661-107 + study results
- Vertex VX14-661-108 + study results
- Vertex VX14-809-109 + study results
- Galapagos GLPG1837-CL-202
- ProQR PQ-010-002 + study results
- PTC124-GD-021e-CF (Extension study)
- Vertex VX15-809-110 (Extension study)
- Vertex VX14-661-109
- Vertex VX15-371-101
- Galapagos GLPG1837-CL-201
- Vertex VX14-661-110 (Extension study)
- Bayer 17020
- ProQR PQ-010-001 + study results
- Vertex VX15-770-123
- Vertex VX15-440-101
- Galapagos-GLPG2222-CL-201
- Galapagos GLPG2222-CL-202
- Vertex VX16-659-001partD
- Vertex VX16-445-001
- Proteostatis PTI-428-01
- Vertex VX16-659-101
- Galapagos GLPG2737-CL-202
- Flatley FDL169-2015-04
- Vertex VX17-659-102
- Vertex VX17-659-103
- Vertex VX17-445-102
- Vertex VX17-445-103
- Vertex VX16-661-115
- Galapagos GLPG2737-CL-105
- Vertex VX17-659-105
- Vertex VX17-661-116
- Vertex VX17-445-105
- Vertex VX18-121-101
- Vertex VX16-809-121
- Flatley FDL169-2018-10
- Proteostasis PTI-808-01
- Proteostasis PTI-801-01
- Vertex VX18-445-109
- Vertex VX18-445-106
- Vertex VX18-445-104
- Vertex VX18-445-110
- Vertex VX19-445-107
- Vertex VX18-445-113
- Vertex VX19-445-116
- Vertex VX20-445-119
- Vertex VX20-445-118
- Vertex VX19-445-117
- Vertex VX20-445-111
- Eloxx EL-004
- Vertex VX15-770-124
- Abbvie M19-530
- Vertex VX19-445-115
- Vertex VX20-445-126
- Vertex VX20-445-121
- Vertex VX15-770-126
- Abbvie M19-771
- Vertex VX20-121-102
- Vertex VX20-121-103
- Vertex VX21-445-124
- Vertex VX21-445-125
Mucus Alteration
Mucociliary clearance
Anti-infective
- MPEX Pharmaceuticals: MPEX-209 - Includes Study Results
- Insmed Arikace TR02-108 - Includes Study Results
- Novartis CTBM100C2401 + study results
- Gilead GS-US-205-0162 "Alpine" - Includes Study Results
- Gilead GS-US-205-0160 "PALS" + study results
- Insmed Arikace TR02-110 (extension) + study results
- Novartis CTBM100C2401E1 (extension) + study results
- Mukoviszidose Institut gGmbH: Efficacy Study of IgY (Antibody Against Pseudomonas aeruginosa) in Cystic Fibrosis Patients (PsAer-IgY)
- Novartis CTBM100C2304 EARLY study (Tobi in children) + study results
- TORPEDO-CF
- Alaxia ALX-009-CL-038
- cASPerCF
- Synspira SNSP113-19-201
Anti-inflammation and Anti-infective
Anti-inflammation
- GSK CF2110399 - includes Study Results
- Corbus JBT101-CF-001 + study results
- Celtaxsys CTX-4430-CF-201
- Gilead GS-US-404-1808
- Corbus JBT101-CF-002
Bronchodilatators
- Boehringer Tiotropium Phase 2 - includes Study Results (in PDF)
- Boehringer Tiotropium Phase 3 - includes Study Results
Restore Airway Surface Liquid
- Pharmaxis DPM-CF-204 + study results
- Pharmaxis DPM-CF-303 (adults) + study results
- Novartis CQBW276X2201
- Boehringer 1399-0003
- Ionis ION-827359-CS1